ETROLIZUMAB VERSUS INFLIXIMAB FOR TREATING PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 GARDENIA STUDY

Silvio Danese  ¹     Jean-Frédéric Colombel  ²     Milan Lukas  ³     Javier Gisbert  ⁴     Geert R. D'Haens  ⁵     Bu Hayee  ⁶     Remo Pannacione  ⁷     Hyun-Soo Kim  ⁸     Walter Reinisch  ⁹     Helen Tyrrell  ¹⁰     Young Oh  ¹¹     Swati Tole  ¹¹     Akiko Chai  ¹¹     Kirsten Chamberlain-James  ¹¹     Meina Tao Tang  ¹¹     Stefan Schreiber  ^12    
1 Humanitas University, Milan, Italy
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Charles University, Prague, Czech Republic
⁴ La Princesa University Hospital, IIS-IP and CIBEREHED, Madrid, Spain
⁵ Amsterdam University Medical Center, Amsterdam, Netherlands
⁶ Kings College London, London, United Kingdom
⁷ University of Calgary, Calgary, Canada
⁸ Yonsei University Wonju College of Medicine, Wonju, Korea (Republic of)
⁹ Medical University of Vienna, Vienna, Austria
¹⁰ Roche Products Limited, Welwyn Garden City, United Kingdom
¹¹ Genentech, Inc., South San Francisco, United States
¹² Christian-Albrechts University, Kiel, Germany

Topic
IBD

Session
UEG Research Prize 2020 Session

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)